Literature DB >> 17387139

Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes.

Lukas A Altwegg1, Michel Neidhart, Martin Hersberger, Simone Müller, Franz R Eberli, Roberto Corti, Marco Roffi, Gabor Sütsch, Steffen Gay, Arnold von Eckardstein, Manfred B Wischnewsky, Thomas F Lüscher, Willibald Maier.   

Abstract

AIMS: We investigated whether myeloid-related protein 8/14 complex (MRP8/14) expressed by infiltrating monocytes and granulocytes may represent a mediator and early biomarker of acute coronary syndromes (ACS). METHODS AND
RESULTS: Immunohistochemistry of coronary thrombi was done in 41 ACS patients. Subsequently, levels of MRP8/14 were assessed systemically in 75 patients with ACS and culprit lesions, with stable coronary artery disease (CAD), or with normal coronary arteries. In a subset of patients, MRP8/14 was measured systemically and at the site of coronary occlusion. Macrophages and granulocytes, but not platelets stained positive for MRP8/14 in 76% of 41 thrombi patients. In ACS, local MRP8/14 levels [22.0 (16.2-41.5) mg/L] were increased when compared with systemic levels [13.4 (8.1-14.7) mg/L, P = 0.03]. Systemic levels of MRP8/14 were markedly elevated [15.1 (12.1-21.8) mg/L, P = 0.001] in ACS when compared with stable CAD [4.6 (3.5-7.1) mg/L] or normals [4.8 (4.0-6.3) mg/L]. Using a cut-off level of 8 mg/L, MRP8/14 but not myoglobin or troponin, identified ACS presenting within 3 h from symptom onset.
CONCLUSION: In ACS, MRP8/14 is markedly expressed at the site of coronary occlusion by invading phagocytes. The occurrence of elevated MRP8/14 in the systemic circulation prior to markers of myocardial necrosis makes it a prime candidate for the detection of unstable plaques and management of ACS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17387139     DOI: 10.1093/eurheartj/ehm078

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  61 in total

1.  The elevated serum S100A8/A9 during acute myocardial infarction is not of cardiac myocyte origin.

Authors:  Chang-Qing Du; Lin Yang; Jie Han; Jian Yang; Xue-Yan Yao; Xiao-Sheng Hu; Shen-Jiang Hu
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

2.  The molecular mechanisms driving physiological changes after long duration space flights revealed by quantitative analysis of human blood proteins.

Authors:  Daria N Kashirina; Andrew J Percy; Liudmila Kh Pastushkova; Christoph H Borchers; Kirill S Kireev; Vladimir A Ivanisenko; Alexey S Kononikhin; Eugene N Nikolaev; Irina M Larina
Journal:  BMC Med Genomics       Date:  2019-03-13       Impact factor: 3.063

3.  Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest pain.

Authors:  Amit N Vora; Marc P Bonaca; Christian T Ruff; Petr Jarolim; Sabina Murphy; Kevin Croce; Marc S Sabatine; Daniel I Simon; David A Morrow
Journal:  J Thromb Thrombolysis       Date:  2012-08       Impact factor: 2.300

4.  Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study.

Authors:  Kristin Angel; Sella A Provan; Magne K Fagerhol; Petter Mowinckel; Tore K Kvien; Dan Atar
Journal:  Am J Hypertens       Date:  2012-03-01       Impact factor: 2.689

Review 5.  Biomarkers in acute kidney injury - pathophysiological basis and clinical performance.

Authors:  E V Schrezenmeier; J Barasch; K Budde; T Westhoff; K M Schmidt-Ott
Journal:  Acta Physiol (Oxf)       Date:  2016-08-25       Impact factor: 6.311

6.  Calprotectin in rheumatoid arthritis : association with disease activity in a cross-sectional and a longitudinal cohort.

Authors:  Miriam García-Arias; Dora Pascual-Salcedo; Susana Ramiro; Marie-Eve Ueberschlag; Thomas M Jermann; Carlos Cara; Emilio Martín-Mola; Alejandro Balsa
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

7.  Anti-atherogenic properties of resveratrol: 4-week resveratrol administration associated with serum concentrations of SIRT1, adiponectin, S100A8/A9 and VSMCs contractility in a rat model.

Authors:  Michał Wiciński; Bartosz Malinowski; Mateusz M Węclewicz; Elżbieta Grześk; Grzegorz Grześk
Journal:  Exp Ther Med       Date:  2017-03-02       Impact factor: 2.447

8.  Beneficial effects of quinoline-3-carboxamide (ABR-215757) on atherosclerotic plaque morphology in S100A12 transgenic ApoE null mice.

Authors:  Ling Yan; Per Bjork; Radu Butuc; Joseph Gawdzik; Judy Earley; Gene Kim; Marion A Hofmann Bowman
Journal:  Atherosclerosis       Date:  2013-02-28       Impact factor: 5.162

9.  Myeloid-related protein-8/14 is critical for the biological response to vascular injury.

Authors:  Kevin Croce; Huiyun Gao; Yunmei Wang; Toshifumi Mooroka; Masashi Sakuma; Can Shi; Galina K Sukhova; René R S Packard; Nancy Hogg; Peter Libby; Daniel I Simon
Journal:  Circulation       Date:  2009-07-20       Impact factor: 29.690

10.  Myeloid-related protein 8/14 complex describes microcirculatory alterations in patients with type 2 diabetes and nephropathy.

Authors:  Klaus Burkhardt; Sonja Schwarz; Chengrui Pan; Felix Stelter; Konstantin Kotliar; Maxilian Von Eynatten; Daniel Sollinger; Ines Lanzl; Uwe Heemann; Marcus Baumann
Journal:  Cardiovasc Diabetol       Date:  2009-02-20       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.